文献速递其他结缔组织病

NOTCH4功能获得性变异破坏系统性硬化症血管生成

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2026-02-04

该研究聚焦血管表型更重、预后更差的非洲裔美国SSc患者,结合遗传学、单细胞RNA测序、功能实验和小鼠模型探索NOTCH4在SSc血管病变中的作用。基于基因的检测发现NOTCH4与SSc及其严重血管病变存在外显子组水平显著关联,风险单倍型在非洲裔美国SSc患者中富集;SSc相关NOTCH4变异增加NOTCH4表达和信号传导,导致血管生成减少和内皮间质转化增加,而遗传、化学、抗体或FDA批准药物抑制NOTCH4信号可挽救血管生成并使内皮间质转化恢复基线。

要点

  • NOTCH4与SSc及其严重血管病变存在外显子组水平显著关联。
  • SSc相关NOTCH4变异增加NOTCH4表达和信号传导,减少血管生成并增加内皮间质转化。
  • 抑制NOTCH4信号可挽救血管生成并使内皮间质转化恢复基线。

核心结论

  • NOTCH4变异与SSc发病及血管病变相关,部分解释非洲裔美国人中SSc患病率增加。
  • 研究强调需进一步开展抑制NOTCH4通路的临床研究以治疗SSc血管和纤维化表现。

研究设计与样本

  • 研究聚焦血管表型更重、预后更差的非洲裔美国SSc患者,结合遗传学、单细胞RNA测序、功能实验和小鼠模型。

主要发现

  • 基于基因的检测发现NOTCH4与SSc在外显子组水平显著关联(P = 1.6 × 10-7),与严重血管病变亦显著关联(P = 3.5 × 10-7)。
  • 由错义变异(c.2824C>T)和启动子变异(c.-117G>A)定义的风险单倍型在非洲裔美国SSc患者中富集(11%),对照组中较少。
  • 该单倍型在非洲裔美国SSc患者中的人群归因风险为2.6%,比欧洲裔美国人高52倍。
  • SSc相关NOTCH4变异增加NOTCH4表达和信号传导,导致血管生成减少和内皮间质转化增加。
  • 遗传、化学、抗体或FDA批准药物抑制NOTCH4信号可挽救血管生成并使内皮间质转化恢复基线。

临床怎么用

  • NOTCH4通路抑制可能作为治疗SSc血管和纤维化表现的策略,尚需进一步研究和临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Vasculopathy and fibrosis are central to the pathogenesis of systemic sclerosis (SSc) and their genetic underpinnings are largely unknown. Here, we sought to examine the aetiology of severe vascular phenotypes and poorer outcomes in African American (AA) patients with SSc. METHODS: The study focuses on AA patients with SSc who have more severe vascular phenotypes and poorer outcomes and combines genetics, single-cell RNA sequencing, functional assays, and a mouse model to explore the role of NOTCH4 in SSc vasculopathy and the potential for NOTCH4-directed therapies. RESULTS: Gene-based testing identified NOTCH4 association at an exome-wide significance with SSc (P = 1.6 × 10-7) and patients with severe vascular disease (P = 3.5 × 10-7). The risk haplotype defined by the missense (c.2824C>T) and promoter (c.-117G>A) variants was enriched in AAs with SSc (11%) vs controls, and the population attributable risk due to this haplotype in AAs with SSc was 2.6%, which was 52-fold higher than in European Americans. The SSc-associated NOTCH4 variants increased NOTCH4 expression and signalling, leading to decreased angiogenesis and increased endothelial-to-mesenchymal transition (EndoMT). Nailfold capillary abnormalities, decreased angiogenesis, and fibrosis of the vascular lumen are commonly seen in SSc. Genetic, chemical, antibody, or Food and Drug Administration-approved drug inhibition of NOTCH4 signalling rescued angiogenesis and returned EndoMT to baseline. CONCLUSIONS: NOTCH4 variants are associated with SSc pathogenesis and vasculopathy, partly explaining the increased prevalence of SSc in AAs. The study highlights the need for further research and clinical trials in the inhibition of the NOTCH4 pathway as a strategy to treat the vascular and fibrotic manifestations of SSc.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kaundal U, Tsou PS, Sahu M, et al. Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis. Ann Rheum Dis. 2026. PMID: 41644364. doi:10.1016/j.ard.2025.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。